Sonoma Pharmaceuticals Announces Second Quarter FY 2019 Financial Results and Conference Call
November 01 2018 - 7:05AM
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) today announced that
financial results for its fiscal year 2019 second quarter, ended
September 30, 2018, will be released after the U.S. markets close
on November 8, 2018. The earnings release will be followed by
a conference call at 1:30 p.m. PST on November 8, 2018, to discuss
fiscal second quarter results.
Individuals interested in participating in the conference call
may do so by dialing 877-303-7607 for domestic callers or
973-638-3203 for international callers. Those interested in
listening to the conference call live via the internet may do so at
https://edge.media-server.com/m6/p/b5tvh3bj.
A telephone replay will be available for seven days following
the conclusion of the call by dialing 855-859-2056 for domestic
callers, or 404-537-3406 for international callers, and entering
conference code 3686329. A webcast replay will be available on the
site at http://ir.sonomapharma.com/events.cfm for one year
following the call.
About Sonoma Pharmaceuticals, Inc.Sonoma
Pharmaceuticals is a specialty pharmaceutical company that develops
and markets solutions for the treatment of dermatological
conditions and advanced tissue care. The company’s
products, which are sold throughout the United States and
internationally, have improved outcomes for more than five million
patients globally by reducing infections, itch, pain, scarring
and harmful inflammatory responses. The company's headquarters are
in Petaluma, California, with manufacturing operations in the
United States and Latin America. European marketing and sales
are headquartered in Roermond, Netherlands. More information can be
found at www.sonomapharma.com.
Media and Investor Contact:
Sonoma Pharmaceuticals, Inc.
Bob MillerCFO(925) 787-6218
Sonoma Pharmaceuticals (NASDAQ:SNOA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sonoma Pharmaceuticals (NASDAQ:SNOA)
Historical Stock Chart
From Apr 2023 to Apr 2024